Structure of Afatinib
CAS No.: 850140-72-6
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Afatinib (BIBW 2992) is an orally active, potent, and irreversible dual specificity inhibitor of the ErbB family (EGFR and HER2) with IC50 values of 0.5 nM, 0.4 nM, 10 nM, and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M, and HER2, respectively. Afatinib is used in research on esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC), and gastric cancer.
Synonyms: BIBW 2992
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 850140-72-6 |
Formula : | C24H25ClFN5O3 |
M.W : | 485.94 |
SMILES Code : | O=C(NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1O[C@@H]4COCC4)/C=C/CN(C)C |
Synonyms : |
BIBW 2992
|
MDL No. : | MFCD12407405 |
InChI Key : | ULXXDDBFHOBEHA-CWDCEQMOSA-N |
Pubchem ID : | 10184653 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302 |
Precautionary Statements: | P280-P305+P351+P338 |
Target |
|
In Vitro:
Concentration | Treated Time | Description | References |
Cos-7 cells | 10 nM | two weeks | To screen for cell clones carrying EGFR Exon 20 insertion mutations | PMC5932243 |
ICC10-6 | 100 nM | 10 days | To evaluate the effect of Afatinib alone or in combination with infigratinib on the viability of ICC10-6 cells | PMC9064956 |
ICC21 | 100 nM | 7 days | To evaluate the effect of Afatinib alone or in combination with infigratinib on the viability of ICC21 cells | PMC9064956 |
MKN7 | 0.5 µM | 20 min | To study the effect of Afatinib on EGFR and HER2 in MKN7 cells. Results showed that Afatinib slightly reduced the phosphorylation of EGFR and HER2. | PMC5891041 |
MKN1 | 0.5 µM | 20 min | To study the effect of Afatinib on EGFR in MKN1 cells. Results showed that Afatinib reduced the phosphorylation of EGFR. | PMC5891041 |
NCI-N87 | 0.5 µM | 20 min | To study the effect of Afatinib on HER family RTKs in NCI-N87 cells. Results showed that Afatinib alone or in combination with trastuzumab significantly reduced the phosphorylation of EGFR and HER3. | PMC5891041 |
HCC1937 and HDQP1 cells | 1 µM | 5 days | To evaluate the effect of afatinib in combination with other targeted therapies, the combination of afatinib and dasatinib showed the greatest growth inhibition in HCC1937 and HDQP1 cells. | PMC6987485 |
TNBC cell lines | 0.008 to 5.0 µM | 5 days | To assess the single-agent antiproliferative effects of afatinib, we tested the effect of afatinib on a panel of 14 TNBC cell lines, showing varying IC50 values. | PMC6987485 |
Human cardiac microvascular ECs | 50 ng/mL | 1, 3, or 6 h | To study the effect of VEGF treatment on Nrg1-β1 concentration | PMC6553980 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
Mice | ICC21 subcutaneous xenograft model | Oral | 15 mg/kg | Once daily for 21 days | To evaluate the anti-tumor effect of Afatinib alone or in combination with infigratinib in the ICC21 subcutaneous xenograft model | PMC9064956 |
Mice | Xenograft model | Subcutaneous injection | 20 mg/kg | Once daily for 14 days | The combination treatment significantly slowed tumor growth rate and reduced Ki67 expression, inducing DNA damage | PMC6737096 |
CB17 SCID mice | H2073-SVD and H2073-ASV xenograft models | Oral | 7.5 or 20 mg/kg | Once daily for 14 days | To evaluate the anti-tumor activity of Afatinib in xenograft models carrying EGFR Exon 20 insertion mutations, showing poor efficacy in these models | PMC5932243 |
CB17/lcr-Prkdc SCID/Crl mice | HCC1806 xenograft model | Oral gavage | 10 mg/kg | Once daily for 5 days, followed by 2 days off | To evaluate the antitumour efficacy of combining afatinib and dasatinib in the HCC1806 xenograft model, the combination treatment significantly inhibited tumour growth. | PMC6987485 |
Mice | Non-small cell lung cancer patient-derived xenograft models | Oral | 15 mg/kg | 5 days on, 2 days off, for 4 cycles | Afatinib, in combination with other drugs, completely suppressed tumor growth, showing significant anti-tumor effects. | PMC8763947 |
Mice | C57BL/6J wild-type mice | Oral gavage | 25 mg/kg | For 2 weeks | To study the effect of ErbB signaling inhibition on VEGF-B-induced cardiac hypertrophy | PMC6553980 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT03940976 | Esophageal Squamous Cell Carci... More >>noma Less << | PHASE2 | UNKNOWN | 2020-05-01 | Peking University Cancer Hospi... More >>tal and Institute, Beijing, Beijing, 100142, China Less << |
NCT00425854 | Breast Neoplasms | PHASE2 | COMPLETED | - | 1200.10.3208 Boehringer Ingelh... More >>eim Investigational Site, Brussel, Belgium|1200.10.3201 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium|1200.10.3203 Boehringer Ingelheim Investigational Site, Charleroi, Belgium|1200.10.3205 Boehringer Ingelheim Investigational Site, Gent, Belgium|1200.10.3204 Boehringer Ingelheim Investigational Site, Leuven, Belgium|1200.10.3206 Boehringer Ingelheim Investigational Site, Wilrijk, Belgium|1200.10.49005 Boehringer Ingelheim Investigational Site, Berlin, Germany|1200.10.49007 Boehringer Ingelheim Investigational Site, Düsseldorf, Germany|1200.10.49008 Boehringer Ingelheim Investigational Site, Erlangen, Germany|1200.10.49010 Boehringer Ingelheim Investigational Site, Essen, Germany|1200.10.49003 Boehringer Ingelheim Investigational Site, Kiel, Germany|1200.10.49004 Boehringer Ingelheim Investigational Site, Mainz, Germany|1200.10.49001 Boehringer Ingelheim Investigational Site, München, Germany|1200.10.49006 Boehringer Ingelheim Investigational Site, Wiesbaden, Germany Less << |
NCT03083678 | Chordoma | PHASE2 | ACTIVE_NOT_RECRUITING | 2025-01-31 | Istituto Nazionale dei Tumori:... More >> Fondazione IRCCS, Milan, Italy|Leiden University Medical Center, Leiden, Netherlands|University College London Hospital, London, United Kingdom Less << |
NCT03486509 | Squamous Cell Carcinoma | PHASE2 | UNKNOWN | 2020-07-01 | - |
NCT04640870 | Non Small Cell Lung Cancer|EGF... More >>-R Positive Non-Small Cell Lung Cancer|EGFR Gene Mutation Less << | COMPLETED | 2025-05-20 | - | |
NCT01746251 | Non Small Cell Lung Cancer | PHASE2 | UNKNOWN | 2025-11-21 | Stanford University, Palo Alto... More >>, California, 94304, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02115, United States|Massachusetts General Hospital, Boston, Massachusetts, 02115, United States|Memorial Sloan Kettering, New York, New York, 10065, United States Less << |
NCT00875433 | Neoplasms | PHASE2 | COMPLETED | - | 1200.24.4403 Boehringer Ingelh... More >>eim Investigational Site, Guildford, United Kingdom|1200.24.4402 Boehringer Ingelheim Investigational Site, London, United Kingdom|1200.24.4404 Boehringer Ingelheim Investigational Site, London, United Kingdom|1200.24.4401 Boehringer Ingelheim Investigational Site, Sutton, United Kingdom Less << |
NCT01542437 | Non-Small Cell Lung Cancer|EGF... More >>R|HER-2 Less << | PHASE2 | COMPLETED | 2025-06-17 | National Cancer Institute of M... More >>exico, Mexico city, Distrito Federal, 14080, Mexico Less << |
NCT00525148 | Carcinoma, Non-Small-Cell Lung | PHASE2 | COMPLETED | 2025-08-15 | 1200.22.28 Boehringer Ingelhei... More >>m Investigational Site, Bakersfield, California, United States|1200.22.32 Boehringer Ingelheim Investigational Site, Beverly Hills, California, United States|1200.22.4 Boehringer Ingelheim Investigational Site, Mission Hills, California, United States|1200.22.16 Boehringer Ingelheim Investigational Site, Orange, California, United States|1200.22.19 Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States|1200.22.29 Boehringer Ingelheim Investigational Site, North Miami Beach, Florida, United States|1200.22.10 Boehringer Ingelheim Investigational Site, Atlanta, Georgia, United States|1200.22.18 Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States|1200.22.3 Boehringer Ingelheim Investigational Site, Bethesda, Maryland, United States|1200.22.14 Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States|1200.22.24 Boehringer Ingelheim Investigational Site, Flint, Michigan, United States|1200.22.5 Boehringer Ingelheim Investigational Site, Minneapolis, Minnesota, United States|1200.22.15 Boehringer Ingelheim Investigational Site, New York, New York, United States|1200.22.26 Boehringer Ingelheim Investigational Site, New York, New York, United States|1200.22.1 Boehringer Ingelheim Investigational Site, Rochester, New York, United States|1200.22.27 Boehringer Ingelheim Investigational Site, Syracuse, New York, United States|1200.22.25 Boehringer Ingelheim Investigational Site, Valhalla, New York, United States|1200.22.6 Boehringer Ingelheim Investigational Site, Canton, Ohio, United States|1200.22.7 Boehringer Ingelheim Investigational Site, Wynnewood, Pennsylvania, United States|1200.22.22 Boehringer Ingelheim Investigational Site, Mt. Pleasant, South Carolina, United States|1200.22.31 Boehringer Ingelheim Investigational Site, Fairfax, Virginia, United States|1200.22.40 Boehringer Ingelheim Investigational Site, Renton, Washington, United States|1200.22.33 Boehringer Ingelheim Investigational Site, Seattle, Washington, United States|1200.22.88604 Taichung Veterans General Hospital, Taichung, Taiwan|1200.22.88605 China Medical University Hospital, Taichung, Taiwan|1200.22.88606 Boehringer Ingelheim Investigational Site, Tainan, Taiwan|1200.22.88607 Boehringer Ingelheim Investigational Site, Taipei City, Taiwan|1200.22.88601 National Taiwan University Hospital, Taipei, Taiwan|1200.22.88602 Veterans General Hospital, Taipei, Taiwan|1200.22.88603 Chang Gung Memorial Hosp-Linkou, Taoyuan, Taiwan Less << |
NCT02044380 | Carcinoma, Non-Small-Cell Lung | PHASE3 | COMPLETED | 2025-02-16 | Boehringer Ingelheim Investiga... More >>tional Site, Barrie, Ontario, Canada|Boehringer Ingelheim Investigational Site, London, Ontario, Canada|Boehringer Ingelheim Investigational Site, Newmarket, Ontario, Canada|Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada Less << |
NCT02171728 | Neoplasms | PHASE1 | COMPLETED | - | - |
NCT02511847 | Triple Negative Breast Cancer | PHASE2 | UNKNOWN | 2025-07-17 | National Taiwan University Hos... More >>pital, Taipei City, 110, Taiwan Less << |
NCT04201756 | Lung Adenocarcinoma Stage III|... More >>EGFR Gene Mutation Less << | PHASE2 | COMPLETED | 2022-08-30 | Shanghai Pulmonary Hospital, S... More >>hang'ai, Shanghai, 200433, China Less << |
NCT02171650 | Neoplasms | PHASE1 | COMPLETED | - | - |
NCT04909073 | Non-Small Cell Lung Cancer|Epi... More >>dermal Growth Factor Receptor Mutation Less << | RECRUITING | 2025-12-25 | Nationa University Hospital, S... More >>ingapore, Singapore Less << | |
NCT01415674 | Carcinoma, Squamous Cell of He... More >>ad and Neck Less << | PHASE2 | COMPLETED | 2025-12-21 | CHU d'Angers, Angers, France|I... More >>nstitut de cancérologie de l'Ouest - Site Paul Papin, Angers, France|Centre Fran?ois Baclesse, Caen, 14000, France|Centre Léon Bérard, Lyon, 69373, France|Chu de Nantes, Nantes, France|Centre Antoine Lacassagne, Nice, 06189, France|Institut Curie, Paris, 75248, France|Institut de cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France|Institut Claudius Regaud, Toulouse, 31052, France|Centre Alexis Vautrin, Vandoeuvre les Nancy, 54511, France|Institut Gustave Roussy, Villejuif, 94800, France Less << |
NCT05519917 | Chordoma of Clivus | PHASE2 | NOT_YET_RECRUITING | 2025-12-30 | Huashan Hospital, Shanghai, Sh... More >>anghai, 200000, China Less << |
NCT00431067 | Breast Neoplasms | PHASE2 | COMPLETED | - | 1200.11.3 Boehringer Ingelheim... More >> Investigational Site, Scottsdale, Arizona, United States|1200.11.7 Boehringer Ingelheim Investigational Site, Encinitas, California, United States|1200.11.4 Boehringer Ingelheim Investigational Site, Santa Monica, California, United States|1200.11.2 Boehringer Ingelheim Investigational Site, Tampa, Florida, United States|1200.11.1 Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States|1200.11.5 Boehringer Ingelheim Investigational Site, Chapel Hill, North Carolina, United States|1200.11.4401 Boehringer Ingelheim Investigational Site, Bournemouth, United Kingdom|1200.11.4402 Boehringer Ingelheim Investigational Site, Crownhill, Plymouth, United Kingdom|1200.11.4406 Boehringer Ingelheim Investigational Site, Guildford, United Kingdom|1200.11.4405 Boehringer Ingelheim Investigational Site, London, United Kingdom|1200.11.4404 Boehringer Ingelheim Investigational Site, Poole, United Kingdom|1200.11.4403 Boehringer Ingelheim Investigational Site, Truro, United Kingdom Less << |
NCT01074177 | Non-small Cell Lung Cancer|EGF... More >>R Mutations Less << | COMPLETED | 2025-03-17 | Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States Less << | |
NCT02271906 | Lung Cancer | PHASE2 | TERMINATED | 2017-08-16 | University of Texas MD Anderso... More >>n Cancer Center, Houston, Texas, 77030, United States Less << |
NCT02629523 | Lung Neoplasms|EGFR Gene Mutat... More >>ion Less << | PHASE2 | COMPLETED | 2020-05-11 | Chonnam National University Hw... More >>asun Hospital, Hwasun, Jeonnam, 58128, Korea, Republic of Less << |
NCT02423525 | Brain Cancer | PHASE1 | COMPLETED | 2025-08-21 | John Wayne Cancer Institute, S... More >>anta Monica, California, 90404, United States Less << |
NCT02506517 | Solid Tumors | PHASE2 | COMPLETED | 2023-05-04 | Princess Margaret Cancer Centr... More >>e, Toronto, Ontario, M5G 2M9, Canada Less << |
NCT02183883 | Non-small Cell Lung Cancer | PHASE2 | COMPLETED | 2023-03-22 | Aberdeen Royal Infirmary (NHS ... More >>Grampian), Aberdeen, United Kingdom|Heart of England NHS Foundation Trust, Birmingham, United Kingdom|Beatson West of Scotland Cancer Centre (NHS Greater Glasgow & Clyde), Glasgow, United Kingdom|Barnet and Chase Farm Hospitals (Royal Free London NHS Foundation Trust), London Borough Of Barnet, United Kingdom|University College London Hospitals NHS Foundation Trust, London, NW1 2BU, United Kingdom|Cr Uk & Ucl Ctc, London, W1T 4TJ, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom Less << |
NCT02171702 | Neoplasms | PHASE1 | COMPLETED | - | - |
NCT02369484 | NSCLC | PHASE2 | COMPLETED | 2017-09-15 | Universit?tsklinikum K?ln, K?l... More >>n, Germany|NKI-AVL, Amsterdam, Netherlands|Vall d'Hebron University Hospital, Barcelona, Spain|CHUV, Lausanne, Switzerland|USZ, Zürich, Switzerland Less << |
NCT06648096 | Fanconi Anemia|Head and Neck S... More >>quamous Cell Carcinoma Less << | PHASE1|PHASE2 | RECRUITING | 2025-12-28 | Medizinische Hochschule Hannov... More >>er, Hannover, Germany|Hospital de la Santa Creu i Sant Pau, Barcelona, Catalu?a, Spain Less << |
NCT01209650 | Carcinoma, Non-Small-Cell Lung | APPROVED_FOR_MARKETING | - | 1200.47.1 Boehringer Ingelheim... More >> Investigational Site, North Ryde, New South Wales, Australia Less << | |
NCT02695290 | Carcinoma, Non-Small-Cell Lung... More >>|ErbB Receptors Less << | PHASE4 | TERMINATED | 2016-08-26 | 1200.208.10032 Boehringer Inge... More >>lheim Investigational Site, Fountain Valley, California, United States Less << |
NCT04533321 | Squamous Cell Carcinoma | PHASE2 | UNKNOWN | 2025-09-23 | National University Hospital, ... More >>Singapore, Singapore Less << |
NCT02171663 | Neoplasms | PHASE1 | COMPLETED | - | - |
NCT01931306 | Carcinoma, Non-Small-Cell Lung | APPROVED_FOR_MARKETING | - | The Catholic University of Kor... More >>ea, Bucheon St.Mary's Hospital, Bucheon, 14647, Korea, Republic of|Gachon University Gil Medical Center, Incheon, 405-760, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeonnam, 519-763, Korea, Republic of|Gyeongsang National University Hospital, Jinju, 660-702, Korea, Republic of|The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, 06591, Korea, Republic of|Severance Hospital, Seoul, 120-752, Korea, Republic of|Samsung Medical Center, Seoul, 135-710, Korea, Republic of|SMG-SNU Boramae Medical Center, Seoul, 156-707, Korea, Republic of Less << | |
NCT02514174 | Carcinoma, Non-Small-Cell Lung... More >>|ErbB Receptors Less << | PHASE4 | COMPLETED | 2019-04-25 | Mayo Clinic-Arizona, Scottsdal... More >>e, Arizona, 85250, United States|Pacific Cancer Medical Center, Inc., Anaheim, California, 92801, United States|City of Hope, Duarte, California, 91010, United States|Compassionate Care Research Group, Inc. at Compassionate Cancer Care Medical Group, Inc., Fountain Valley, California, 92708, United States|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, 90017, United States|University of Miami, Miami, Florida, 33136, United States|Ingalls Memorial Hospital, Harvey, Illinois, 60426, United States|Baystate Health D'Amour Center for Cancer Care, Springfield, Massachusetts, 01199, United States|Montefiore Medical Center, Bronx, New York, 10467, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, 19096, United States Less << |
NCT01953913 | Carcinoma, Non-Small-Cell Lung | PHASE3 | COMPLETED | 2018-07-06 | 307 Hospital of PLA, Beijing, ... More >>100071, China|Beijing Cancer Hospital, Beijing, 100142, China|Chinese PLA General Hospital, Beijing, 100853, China|Jilin Province Cancer Hospital, Changchun, China|Guangdong Provincial People's Hospital, Guangzhou, 510080, China|Zhejiang Cancer Hospital, Hangzhou, 310022, China|Lin Yi Tumor Hospital, Linyi, 276002, China|Jiangsu Cancer Hospital, Nanjing, 210000, China|Shanghai Chest Hospital, Shanghai, 200030, China|Fudan University Shanghai Cancer Center, Shanghai, 200032, China|Shanghai Pulmonary Hospital, Shanghai, 200433, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China|Queen Mary Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital, Shatin, Hong Kong|Vikram Hospital, Bangalore, 560052, India|HCG Hospital, Bengaluru, 560027, India|P VS Hospital Pvt Ltd, Calicut, 673002, India|V S Hospital, Chennai, 600031, India|Max Super Speciality Hospital, Delhi, Delhi, 110092, India|Global Hospitals, Hyderabad, 500004, India|Basavatarakam Indo - American Cancer Hospital & Research Ins, Hyderabad, 500034, India|SEAROC Cancer Centre, Jaipur, 302004, India|B. P. Poddar Hospital & Medial Research Ltd, Kolkata,West Bengal, 700053, India|Asirvatham Multispeciality Hospital, Madurai, 625 020, India|Curie Manavata Cancer Centre, Maharashtra, 422 004, India|Shatabdi Superspeciality Hospital, Maharashtra, 422005, India|Prince Aly Khan Hospital, Mumbai, 400010, India|Ruby Hall Clinic, Pune, 411001, India|National Cancer Centre, Singapore, 169610, Singapore|E-Da Hospital, Kaohsiung, 824, Taiwan|NCKUH, Tainan, 704, Taiwan|Tri-Service General Hospital, Taipei, 11490, Taiwan|Chang-Gung Memorial Hospital, Linkou, Taoyuan County, 333, Taiwan Less << |
NCT02491099 | HER2/Neu+ Uterine Serous Carci... More >>noma Less << | PHASE2 | RECRUITING | 2025-07-25 | University of Arizona Cancer C... More >>enter, Tucson, Arizona, 85724, United States|Yale New Haven Hospital, New Haven, Connecticut, 06510, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States Less << |
NCT02876081 | SMALL CELL LUNG CARCINOMA | PHASE2 | WITHDRAWN | 2025-12-18 | Groupe Hospitalier Paris Saint... More >> Joseph, Paris, Ile-de-France, 75014, France Less << |
NCT04206787 | Non-squamous, Non-Small Cell L... More >>ung Cancer Less << | COMPLETED | 2023-12-22 | Peking Union Medical College H... More >>ospital, Beijing, 100730, China|West China Hospital, Chengdu, 610041, China|The First Afiliated Hospital, Sun Yet-sen University, Guangzhou, 510080, China|First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China|Hainan Cancer Hospital, Haikou, 570312, China|The First Affiliated Hospital, Zhejiang University, Hangzhou, 310003, China|China Shenyang Chest Hospital, Shenyang, 110000, China|Shenzhen People's Hospital, Shenzhen, 518020, China|The First Affiliated Hospital of Zhengzhou Unviersity, Zhengzhou, 450052, China|Zhongshan People's Hospital, Zhongshan, 528403, China Less << | |
NCT02780687 | Urologic Neoplasms | PHASE2 | COMPLETED | 2019-09-02 | INS Bergonié, Bordeaux, 33076,... More >> France|CTR Leon Berard, Lyon, 69373, France|INS Cancérologie du Gard, N?mes, 30029, France|HOP Saint-Louis, Paris, 75010, France|HOP Cochin, Paris, 75014, France|HOP Européen G. Pompidou, Paris, 75015, France|HOP Foch, Suresnes, 92150, France|INS Universitaire du Cancer, Toulouse, 31059, France|INS Gustave Roussy, Villejuif, 94805, France|Ospedale San Donato di Arezzo, Arezzo, 52100, Italy|A.O. San Camillo Forlanini, Roma, 00152, Italy|Hospital Germans Trias i Pujol, Badalona, 08916, Spain|Hospital del Mar, Barcelona, 08003, Spain|Hospital Santa Creu i Sant Pau, Barcelona, 08025, Spain|Hospital Clínic de Barcelona, Barcelona, 08036, Spain|Hospital Vall d'Hebron, Barcelona, 08038, Spain|Hospital Universitario de Elche, Elche, 03202, Spain|Hospital Universitari de Girona Doctor Josep Trueta, Girona, 17007, Spain|Hospital Duran i Reynals, L'Hospitalet de Llobregat, 08908, Spain|Hospital Universitario Lucus Augusti, Lugo, 27003, Spain|Hospital Ramón y Cajal, Madrid, 28034, Spain|Hospital Clínico San Carlos, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital La Paz, Madrid, 28046, Spain|CIO Clara Campal, Madrid, 28050, Spain|Hospital Son Espases, Palma de Mallorca, 07010, Spain|CS Parc Taulí, Sabadell, 08208, Spain|Hospital Virgen Macarena, Sevilla, 41009, Spain|Hospital Virgen del Rocío, Sevilla, 41013, Spain|Instituto Valenciano de Oncología, Valencia, 46009, Spain Less << |
NCT04132102 | Lung Squamous Cell Carcinoma | PHASE4 | UNKNOWN | 2021-08-31 | Shanghai Chest Hospital, Shang... More >>hai, Shanghai, 200030, China Less << |
NCT02208843 | Carcinoma, Non-Small-Cell Lung | PHASE4 | COMPLETED | 2017-06-13 | Clinical Research Center, Alex... More >>andria University Hospital, Alexandria, 21131, Egypt|National Cancer Institute, Cairo University, Cairo, 11796, Egypt|Kasr Al Ainy Hospital, Cairo, 12311, Egypt|Nilai Medical Centre, Nilai, 71800, Malaysia|Baguio General Hospital and Medical Center, Baguio City, 2600, Philippines|St. Luke's Medical Center, Taguig, 1634, Philippines|University Clinical Center, Gdansk, Gdansk, 80-952, Poland|Specialist Hospital, Szczecin-Zdunowo, Szczecin-Zdunowo, 70-891, Poland|Oncol Centre M Sklodowska-Curie, Dept of Lung & Chest Cancer, Warsaw, 02-781, Poland|Braila County Emergency Hospital, Medical Oncology, Braila, 810303, Romania|Institute of Oncology 'Prof. Dr. Alexandru Trestioreanu', Bucharest, 022328, Romania|Sf. Nectarie Oncology Center, Craiova, Craiova, 200347, Romania|Regional Oncology Institute of Iasi, Medical Oncology, Iasi, 700483, Romania|Institute for Oncol & Radiol of Serbia, Clinic f. Med. Onco., Belgrade, 11000, Serbia|Clinical Center of Serbia, Belgrade, 11129, Serbia|Clinical Center Kragujevac, Kragujevac, 34000, Serbia|Inst. for Pulm. Diseases of Vojvodine, Clinic f. Pulm. Oncol, Sremska Kamenica, 21204, Serbia|Wattanosoth Hospital, Bangkok, 10310, Thailand|King Chulalongkorn Memorial Hospital, Bangkok, 10330, Thailand|Rajavithi Hospital, Bangkok, 10400, Thailand|Songklanagarind Hospital, Songkhla, 90110, Thailand Less << |
NCT02047903 | Carcinoma, Non-Small-Cell Lung | COMPLETED | 2018-12-31 | Multiple Locations, Germany | |
NCT02171637 | Neoplasms | PHASE1 | COMPLETED | - | - |
NCT01679405 | Metastatic Disease | PHASE1 | TERMINATED | 2025-04-16 | I. Medizinische Klinik und Pol... More >>iklinik der Universit?tsmedizin, Mainz, 55131, Germany Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.06mL 0.41mL 0.21mL |
10.29mL 2.06mL 1.03mL |
20.58mL 4.12mL 2.06mL |